AstraZeneca Pharma India Limited has scheduled a virtual one-on-one meeting with institutional investors and analysts for Wednesday, August 19, 2026. The company issued the intimation on August 15, 2026, in compliance with regulatory disclosure norms under the Securities and Exchange Board of India (SEBI) listing regulations.

Meeting details

The interaction is part of the firm's ongoing engagement with market participants. The following table outlines the key parameters of the scheduled meeting:

The company noted that the schedule is subject to change due to exigencies on the part of the company, analyst, or investor. Tanya Sanish, Company Secretary and Compliance Officer, signed the communication addressed to the Manager – Listing at BSE Limited and the National Stock Exchange of India Ltd.

AstraZeneca Pharma India Limited has announced the final voting results of its 47th Annual General Meeting (AGM) held on August 10, 2026. The Scrutinizer’s Report, dated August 11, 2026, and signed by Mr. Vijayakrishna K T, confirms that all five resolutions placed before shareholders were duly passed with the requisite majority.

The meeting, conducted via Video Conferencing and Other Audio Visual Means (VC/OAVM), commenced at 3:18 p.m. after establishing a quorum and concluded at 5:20 p.m. Shareholders exercised their voting rights through remote e-voting from August 6, 2026, to August 9, 2026, and via e-voting during the meeting. A total of 29,932 shareholders were on record as of August 3, 2026. Of these, 42 shareholders attended the meeting through VC/OAVM (one promoter and 41 public), while no shareholders attended in person or through proxy.

Voting Results by Resolution

The promoter group, holding 18.75 million shares (75% of the total equity), voted in favor of 100% of their shares for all five resolutions. Public institutional investors also showed strong support, particularly for the financial statements and dividend declarations.

Key Voting Details

Financial Statements and Dividend: The adoption of the audited financial statements for FY26 and the declaration of a dividend of ₹36 per equity share received unanimous support from promoters and public institutions. Among public non-institutional shareholders, there were only four votes against the financial statements and four against the dividend, representing negligible dissent.

Director Appointments: Ms. Bhavana Agrawal (DIN: 10485441), who retires by rotation, was reappointed as a director. She received 99.97% of the votes polled in her favor. Dissent came primarily from public non-institutional shareholders, who cast 704 votes against her reappointment out of 769,006 polled.

Ms. Shilpa Divekar Nirula (DIN: 06619353) was reappointed as an Independent Director for a second term from December 29, 2026, to December 28, 2031. This special resolution received 98.22% support. Public institutional shareholders showed higher dissent here compared to other resolutions, with 386,356 votes against (17.03% of their polled votes) compared to 1,882,419 votes in favor.

Statutory Auditors: The appointment of BSR & Co. LLP (FRN: 101248W/W-00022) as statutory auditors was approved with 99.99% of votes in favor. Only 799 votes were cast against this resolution, all from public non-institutional shareholders.

Compliance and Regulatory Filings

The proceedings were conducted in accordance with Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has informed the Bombay Stock Exchange and the National Stock Exchange of India Limited regarding the summary of proceedings and the final voting results.

The Scrutinizer, Mr. Vijayakrishna K T (FCS No. 1788, CP No. 980), certified that the e-voting facility provided by National Securities Depository Limited (NSDL) was conducted fairly and transparently. The company secretary, Tanya Sanish, confirmed the compliance with Regulation 44(3) of the SEBI LODR Regulations, 2015.